August 2012
-
Arrowhead Pharmaceuticals said that interim data from the ARORAGE-1001 Phase 1/2a trial of its ARO-RAGE inhaled RNAi therapeutic, which it is developing for the treatment of inflammatory lung diseases, demonstrate reductions in soluble receptor for… Read more . . .
-
Amphastar Pharmaceuticals will pay Eli Lilly $500 million up front, an additional $125 million after one year, and up to $450 million in sales milestone payments for the rights to Baqsimi intranasal dry powder glucagon. The company… Read more . . .
-
Ritedose Corporation, which says that it is the largest manufacturer of albuterol sulfate inhalation solution in the US, announced that it has begun compounding 5 mg/ml albuterol sulfate inhalation solution ampules through the 503B manufacturing process in response… Read more . . .
-
Tiziana Life Sciences has announced plans for development of its foralumab intranasal anti-CD3 monoclonal antibody for two additional indications, Type 1 diabetes and Alzheimer’s disease. Tiziana said that it is initiating a development program for diabetes… Read more . . .
-
Vyne Therapeutics said that an inhaled formulation of its VYN201 pan-BET inhibitor significantly reduced lung fibrosis and hydroxyproline levels in a mouse model of idiopathic pulmonary fibrosis (IPF) at doses of 0.5 mg/ml and 1… Read more . . .
-
Leyden Laboratories has initiated a Phase 1 trial of its intranasal PanFlu CR9114 anti-hemagglutinin stem human antibody in healthy volunteers, the company said. In July 2021, Leyden Labs announced that it had partnered with Nanopharm… Read more . . .
-
Renovion has initiated a Phase 3 clinical study of its ARINA-1 inhaled glutathione / bicarbonate / ascorbic acid for the treatment of bronchiolitis obliterans syndrome (BOS) following bilateral lung transplant. ARINA-1 recently received Fast Track… Read more . . .
-
ReCode Therapeutics, which is developing inhaled mRNA therapeutics for the treatment of primary ciliary dyskinesia and cystic fibrosis, has named John G. Matthews as Senior VP of Clinical Development. ReCode initiated a Phase 1 trial… Read more . . .
-
Satsuma Pharmaceuticals, which was spun out of Shin Nippon Biomedical Laboratories (SNBL) over 6 years ago to develop an intranasal dry powder formulation of dihydroergotamine, has announced that it will now be acquired by SNBL.… Read more . . .
-
Tonix Pharmaceuticals said that it will reduce enrollment in the recently initiated Phase 2 PREVENTION study of TNX-1900 intranasal potentiated oxytocin in migraine patients from about 300 subjects to about 150 subjects, with a goal… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.